Kikuchi-Fujimoto Disease in Patients with Sjögren’s Syndrome

Lida Radfar, Mehdi Radfar, Kathy L. Moser, Robert Hal Scofield

Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, USA.
College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, USA.

DOI: 10.4236/ojpathology.2013.31006                

Abstract

Sjogren’s syndrome is a chronic autoimmune exocrinopathy associated with dry eyes and dry mouth as major clinical manifestations. It is characterized by lymphocytic infiltration of lacrimal and salivary glands and autoantibody production, especially anti-Ro (or SSA) and anti-La (or SSB). Lymphoproliferative disorders are a feature of Sjogren’s syndrome, and can be considered an extraglandular manifestation of the disease. Kikuchi-Fujimoto disease or histiocytic necrotizing lymphadenitis is a rare form of lymphadenitis. It is reported more often in young adult women with localized lymphadenopathy (usually cervical), fever, rashes, and leukopenia. It is a self-limiting disease with resolution within 1 - 4 months in almost all patients. Sjogren’s syndrome has been reported in patients with other systemic diseases including SLE and lymphomas. Here we present a patient with Kikuchi-Fujimoto disease who developed Sjogren’s Syndrome 8 years after her diagnosis of Kikuchi-Fujimoto disease.

Keywords

Sjögren’s Syndrome; Kikuchi-Fujimoto Disease

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	N. Talal and J. J. Bunim, “The Development of Malignant Lymphoma in the Course of Sjogren’s Syndrome,” The American Journal of Medicine, Vol. 36, No. 4, 1964, pp. 529-540. doi:10.1016/0002-9343(64)90101-9
[2]	A. G. Tzioufas, “B-Cell Lymphoproliferation in Primary Sjogren’s Syndrome,” Clinical and Experimental Rheumatology, Vol. 14, Suppl. 14, 1996, pp. S65-S70.
[3]	J. M. Anaya, G. J. Tobon, P. Vega and J. Castiblanco, “Autoimmune Disease Aggregation in Families with Primary Sjogren’s Syndrome,” The Journal of Rheumatology, Vol. 33, No. 11, 2006, pp. 2227-2234.
[4]	J. E. Moyron-Quiroz, J. Rangel-Moreno, K. Kusser, L. Hartson, F. Spraque, S. Goodrich, D. L. Woodland, F. E. Lund and T. D. Randall, “Role of Inducible Bronchus Associated Lymphoid Tissue (iBALT) in Respiratory Immunity,” Nature Medicine, Vol. 10, No. 9, 2004, pp. 927-934. doi:10.1038/nm1091
[5]	S. S. Kassan, T. L. Thomas, H. M. Moutsopoulos, R. Hoover, R. P. Kimberly, D. R. Budman, J. Costa, J. L. Decker and T. M. Chused, “Increased Risk of Lymphoma in Sicca Syndrome,” Annals of Internal Medicine, Vol. 89, No. 6, 1978, pp. 888-892.
[6]	M. Voulgarelis, U. G. Dafni, D. A. Isenberg and H. M. Moutsopoulos, “Malignant Lymphoma in Primary Sjogren’s Syndrome: A Multicenter, Retrospective, Clinical Study by the European Concerted Action on Sjogren’s Syndrome,” Arthritis and Rheumatism, Vol. 42, No. 8, 1999, pp. 1765-1772. doi:10.1002/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V
[7]	M. Kikuchi, “Lymphadenitis Showing Focal Reticulum Cell Hyperplasia with Nuclear Debris and Phagocytosis,” Nippon Ketsueki Gakkai Zasshi, Vol. 35, 1972, pp. 379-380, Japanese.
[8]	Y. Fujimoto, Y. Kozima and K. Yamaguchi, “Cervical Subacute Necrotising Lymphadenitis: A New Clinicopathologic Entity,” Naika, Vol. 20, 1972, pp. 920-927, (Japanese).
[9]	R. F. Dorfman, G. J. Berry, “Kikuchi’s Histiocytic Necrotizing Lymphadenitis: An Analysis of 108 Cases with Emphasis on Differential Diagnosis,” Seminars in Diagnostic Pathology, Vol. 5, No. 4, 1988, pp. 329-345.
[10]	S. D. Hudnall, T. Chen, S. Amr, K. H. Young and K. Henry, “Detection of Human Herpesvirus DNA in Kikuchi-Fujimoto Disease and Reactive Lymphoid Hyperplasia,” International Journal of Clinical and Experimental Pathology, Vol. 1, No. 4, 2008, pp. 362-368.
[11]	H. C. Hollingsworth, S. C. Peiper, L. M. Weiss, M. Raffeld, E. S. Jaffe, “An Investigation of the Viral Pathogenesis of Kikuchi-Fujimoto Disease. Lack of Evidence for Epstein-Barr Virus or Human Herpesvirus Type 6 as the Causative Agents,” Archives of Pathology and Laboratory Medicine, Vol. 118, No. 2, 1994, pp. 134-140.
[12]	G. Hedia, A. Jamel, A. Maher, A. Hanadi, H. Agnes and K. Nidhameddine, “Kikuchi-Fujimoto Disease Associated with Systemic Lupus Erythematosus,” Journal of Clinical Rheumatology, Vol. 11, No. 6, 2005, pp. 341-342. doi:10.1097/01.rhu.0000191539.52897.ee
[13]	O. Meyer, M. F. Kahn, M. Grossin, P. Ribard, N. Belmatoug, F. Morinet and J. C. Fournet, “Parvovirus B19 Infection Can Induce Histiocytic Necrotizing Lymphadenitis (Kikuchi’s Disease) Associated with Systemic Lupus Erythematosus,” Lupus, Vol. 1, No. 1, 1991, pp. 37-41. doi:10.1177/096120339100100107
[14]	B. Tumiati, A. Bellelli, I. Portioli and S. Prandi, “Kikuchi’s Disease in Systemic Lupus Erythematosus: An Independent or Dependent Event?” Clinical Rheumatology, Vol. 10, No. 1, 1991, pp. 90-93. doi:10.1007/BF02208041
[15]	M. D. Eisner, J. Amory, B. Mullaney, L. Tierney and W. S. Browner, “Necrotizing Lymphadenitis Associated with Systemic Lupus Erythematosus,” Seminars in Arthritis and Rheumatism, Vol. 26, No. 1, 1996, pp. 477-482. doi:10.1016/S0049-0172(96)80028-X
[16]	S. Kaur, G. P. Thami and A. J. Kanwar, “Kikuchi’s Disease, Skin and Systemic Lupus Erythematosus,” The British Journal of Dermatology, Vol. 146, No. 1, 2002, pp. 167-168. doi:10.1046/j.1365-2133.2002.4513_4.x
[17]	C. Martinez-Vazquez, G. Hughes, J. Bordon, J. Alonso-Alonso, A. Anibarro-Garcia, E. Redondo-Martinez and F. Touza-Rey, “Histiocytic Necrotizing Lymphadenitis, Kikuchi-Fujimoto’s Disease, Associated with Systemic Lupus Erythematosus,” Oxford Journals Medicine, Vol. 90, No. 8, 1997, pp. 531-533. doi:10.1093/qjmed/90.8.531
[18]	G. A. Chamulak, R. K. Brynes and B. N. Nathwani, “Kikuchi-Fujimoto Disease Mimicking Malignant Lymphoma,” American Journal of Surgical Pathology, Vol. 14, No. 6, 1990, pp. 514-523. doi:10.1097/00000478-199006000-00002
[19]	H. C. Lin, C. Y. Su, C. C. Huang, C. F. Hwang and C. Y. Chien, “Kikuchi’s Disease: A Review and Analysis of 61 Cases,” Otolaryngology Head and Neck Surgery, Vol. 128, No. 5, 2003, pp. 650-653. doi:10.1016/S0194-5998(02)23291-X
[20]	Y. Kucukardali, E. Solmazgul, E. Kunter, O. Oncul, S. Yildirim and M. Kaplan, “Kikuchi-Fujimoto Disease: Analysis of 244 Cases,” Clinical Rheumatology, Vol. 26, No. 1, 2007, pp. 50-54. doi:10.1007/s10067-006-0230-5
[21]	E. M. Tan, A. S. Cohen, J. F. Fries, A. T. Masi, D. J. McShane, N. F. Rothfield, J. G. Schaller, N. Talal and R. J. Winchester, “The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus,” Arthritis and Rheumatism, Vol. 25, No. 11, 1982, pp. 1271-1277. doi:10.1002/art.1780251101
[22]	C. Vitali, S. Bombardieri, R. Jonsson, H. M. Moutsopoulos, E. L. Alexander, S. E. Carsons, T. E. Daniels, P. C. Fox, R. I. Fox, S. S. Kassan, S. R. Pillemer, N. Talal, M. H. Weisman, European Study Group on Classification Criteria for Sjogren’s Syndrome, “Classification Criteria for Sjogren’s Syndrome: A Revisal of the European Criteria Proposed by the American-European Consensus Group,” Annals of Rheumatic Diseases, Vol. 61, No. 6, 2002, pp. 554-558. doi:10.1136/ard.61.6.554
[23]	D. J. Good and R. D. Gascoyne, “Atypical Lymphoid Hyperplasia Mimicking Lymphoma,” Hematology/Oncology Clinics of North America, Vol. 23, No. 4, 2009, pp. 729-745. doi:10.1016/j.hoc.2009.04.005
[24]	R. F. Dorfman, “Histiocytic Necrotizing Lymphadenitis of Kikuchi and Fujimoto,” Archives of Pathology and Laboratory Medicine, Vol. 111, No. 11, 1987, pp. 1026-1029.
[25]	X. Bosch, A. Guilabert, R. Miquel and E. Campo, “Enigmatic Kikuchi-Fujimoto Disease: A Comprehensive Review,” American Journal of Clinical Pathology, Vol. 122, No. 1, 2004, pp. 141-152. doi:10.1309/YF081L4TKYWVYVPQ
[26]	M. Imamura, H. Ueno, A. Matsuura, H. Kamiya, T. Suzuki, K. Kikuchi and T. Onoe, “An Ultrastructural Study of Subacute Necrotizing Lymphadenitis,” The American Journal of Pathology, Vol. 107, No. 3, 1982, pp. 292-299.
[27]	S. Paradela, J. Lorenzo, W. Martínez-Gomez, T. Yebra-Pimentel, L. Valbuena and E. Fonseca, “Interface Dermatitis in Skin Lesions of Kikuchi-Fujimoto’s Disease: A Histopathological Marker of Evolution into Systemic Lupus Erythematosus?” Lupus, Vol. 17, No. 12, 2008, pp. 1127-1135. doi:10.1177/0961203308092161
[28]	A. Sanpavat, P. Wannakrairot and T. Assanasen, “Necrotizing Non-Granulomatous Lymphadenitis: A Clinicopathologic Study of 40 Thai Patients,” The Southeast Asian Journal of Tropical Medicine and Public Health, Vol. 37, No. 3, 2006, pp. 563-570.
[29]	S. Lu, J. Zhang, W. Zhou and X. M. Wang, “Histiocytic Necrotic Lymphadenitis as an Initial Presentation in Two Children with Sjogren’s Syndrome and/or Systemic Lupus Erthematous,” Chinese Journal of Contemporary Pediatrics, Vol. 12, No. 4, 2010, pp. 311-312 (Chinese).
[30]	E. L. Alexander, F. C. Arnett, T. T. Provost and M. B. Stevens, “Sjogren’s Syndrome: Association of Anti-Ro (SS-A) Antibodies with Vasculitis, Hematologic Abnormalities, and Serologic Hyperreactivity,” Annals of Internal Medicine, Vol. 98, No. 2, 1983, pp. 155-159.
[31]	M. Ramos-Casals, R. Solans, J. Rosas, M. T. Camps, A. Gil, J. Del Pino-Montes, J. Calvo-Alen, J. Jimenez-Alonso, M. L. Mico, J. Beltran, R. Belenguer, L. Pallares, GEMESS Study Group, “Primary Sjogren Syndrome in Spain: Clinical and Immunologic Expression in 1010 Patients,” Medicine (Baltimore), Vol. 87, No. 4, 2008, pp. 210-219. doi:10.1097/MD.0b013e318181e6af
[32]	M. Reichlin and R. H. Scofield, “Ro (SS-A) Antibodies,” In: Y Shoenfeld, ME Gershwin and PL Meroni, Eds., Textbook of Autoantibodies, 2nd Edition, Elsevier, Amsterdam, 2006, pp. 783-788.
[33]	M. Soy, H. Peynirci, S. Bilgi, M. K. Adali and S. Guresci, “Kikuchi-Fujimoto Coexisted with Sjogren’s Syndrome,” Clinical Rheumatology, Vol. 26, No. 4, 2007. pp. 607-608. doi:10.1007/s10067-005-0184-z
[34]	Y. Miyashita, M. Yamaguchi and W. Fujimoto, “Painful Indurated Erythema Suggestive of Kikuchi-Fujimoto Disease in a Patient with Primary Sjogren’s Syndrome,” The Journal of Dermatology, Vol. 30, No. 8, 2003, pp. 608-611.